Screener / SEC EDGAR /CIK 0000887359 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vericel Corp VCEL

Compare with peers Embed
FY2025 at a glance

Sales up 16.5%, free cash flow up to $24.7M

XBRL, from each 10-K
RevenueStatements
$276.3M from $237.2M in FY2024
FY2016FY2025
Net incomeStatements
$16.5M from $10.4M in FY2024
FY2016FY2025
Free cash flowStatements
$24.7M from -$5.8M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.32 from $0.20 in FY2024
FY2016FY2025
Operating marginStatements
4.0% from 1.9% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
0.64
Sales (ttm)
324.2M
Net income (ttm)
33.3M
Sales growth
+16.5%
EPS growth
+60.0%
Sales Q/Q
+26.5%
Free cash flow
57.9M
Gross margin
74.5%
Oper. margin
8.3%
Net margin
10.3%
FCF margin
17.9%
ROE
8.7%
ROA
6.4%
R&D / sales
10.0%
Dividend
-
Debt/Eq
-
Curr. ratio
5.13
Cash
133.5M
Op. cash flow (ttm)
65.3M
EBITDA
22.6M
EBITDA margin
8.2%
Quick ratio
4.81
Interest cover
17.53
ROIC
2.7%
FCF after stock pay
-14.0M
Oper. margin low 5y
-10.4%
Tax rate
4.9%
Stock pay / sales
14.0%
Shares out.
51.0M
Shares Y/Y
+0.9%
Book / share
7.53
Cash / share
2.62
Sales / share
6.35
Asset turnover
0.63
Inventory turns
4.02
Days sales out.
112
Sales 3Y CAGR
+18.9%
Sales 5Y CAGR
+17.3%
EPS 5Y CAGR
+39.8%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 276.3M +19.8% a year Net income 16.5M
FY2016 revenue 54.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-19-002007 FY2016 net income -19.6M · NetIncomeLoss, 0001628280-19-002007 54.4M FY2016 FY2017 revenue 63.9M · Revenues, 0001628280-20-002229 FY2017 net income -17.3M · NetIncomeLoss, 0001628280-20-002229 63.9M FY2017 FY2018 revenue 90.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-21-003081 FY2018 net income -8.1M · NetIncomeLoss, 0001628280-21-003081 90.9M FY2018 FY2019 revenue 117.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-22-003661 FY2019 net income -9.7M · NetIncomeLoss, 0001628280-22-003661 117.8M FY2019 FY2020 revenue 124.2M · Revenues, 0001628280-23-004714 FY2020 net income 2.9M · NetIncomeLoss, 0001628280-23-004714 124.2M FY2020 FY2021 revenue 156.2M · Revenues, 0001628280-24-007824 FY2021 net income -7.5M · NetIncomeLoss, 0001628280-24-007824 156.2M FY2021 FY2022 revenue 164.4M · Revenues, 0001628280-25-008447 FY2022 net income -16.7M · NetIncomeLoss, 0001628280-25-008447 164.4M FY2022 FY2023 revenue 197.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-012013 FY2023 net income -3.2M · NetIncomeLoss, 0001628280-26-012013 197.5M FY2023 FY2024 revenue 237.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-012013 FY2024 net income 10.4M · NetIncomeLoss, 0001628280-26-012013 237.2M FY2024 FY2025 revenue 276.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-012013 FY2025 net income 16.5M · NetIncomeLoss, 0001628280-26-012013 276.3M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +39.8% a year FY2020 $0.06 to FY2025 $0.32, 5 years
Book value per share +15.1% a year FY2018 $2.54 to FY2025 $6.80, 7 years
Free cash flow per share +8.5% a year FY2020 $0.32 to FY2025 $0.47, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.32$6.80$0.47
Dec 31, 2024 $0.20$5.65-$0.11
Dec 31, 2023 -$0.07$4.75$0.32
Dec 31, 2022 -$0.35$4.08$0.21
Dec 31, 2021 -$0.16$3.67$0.45
Dec 31, 2020 $0.06$2.84$0.32
Dec 31, 2019 -$0.22$2.51-$0.22
Dec 31, 2018 -$0.20$2.54-$0.08
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $247.4M
  • − All liabilities $133.3M
  • = Net current asset value $114.1M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $354.6M
  • − Other intangible assets $5.6M
  • = Tangible book value $349.0M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

VCEL against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+16.5%50th of 155 · median +10.5%
Net margin
-4.1%15.3%
10.3%59th of 154 · median 6.8%
Return on equity
-5.2%18.5%
8.7%76th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
17.9%41st of 145 · median 10.0%
VCEL and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
VCEL Vericel Corp$324.2M +16.5%74.5%10.3%8.7%17.9%-
TWST Twist Bioscience Corp$431.8M +20.3%52.0%-31.7%-30.7%-21.6%-
PRCT PROCEPT BioRobotics Corp$352.3M +37.2%64.7%-32.6%-34.9%-24.1%0.16
RYTM Rhythm Pharmaceuticals, Inc.$280.7M +45.8%88.2%-69.0%--29.6%1.17
LMAT Lemaitre Vascular Inc$269.4M +13.5%72.0%23.5%14.7%24.9%-
LGND Ligand Pharmaceuticals Inc$253.8M +60.4%-20.3%5.4%35.7%1.17
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $237.2M of sales to $10.4M of profit FY2024

Revenue to Gross profit: $172.1MRevenue to Cost of revenue: $65.1MGross profit to Operating profit: $4.5MGross profit to Operating expenses: $167.6MOperating profit to Net profit: $4.4MOperating profit to Tax: $148KOther income to Net profit: $6.0MOperating expenses to R&D: $24.8MOperating expenses to SG&A: $142.8M Revenue: $237.2M REVENUE $237.2M +20% Y/Y Gross profit: $172.1M · 73% margin GROSS PROFIT $172.1M 73% margin · +27% Y/Y Cost of revenue: $65.1M · 27% of revenue COST OF REVENUE $65.1M 27% of revenue Operating profit: $4.5M · 2% margin OPERATING PROFIT $4.5M 2% margin Other income: $6.0M · 3% of revenue OTHER INCOME $6.0M 3% of revenue Operating expenses: $167.6M · 71% of revenue OPERATING EXPENSES $167.6M 71% of revenue Net profit: $10.4M · 4% margin NET PROFIT $10.4M 4% margin Tax: $148K · 0% of revenue TAX $148K 0% of revenue R&D: $24.8M · 10% of revenue R&D $24.8M 10% of revenue SG&A: $142.8M · 60% of revenue SG&A $142.8M 60% of revenue

From $276.3M of sales to $16.5M of profit FY2025

Revenue to Gross profit: $205.6MRevenue to Cost of revenue: $70.7MGross profit to Operating profit: $11.0MGross profit to Operating expenses: $194.6MOperating profit to Net profit: $10.2MOperating profit to Tax: $859KOther income to Net profit: $6.3MOperating expenses to R&D: $27.6MOperating expenses to SG&A: $167.0M Revenue: $276.3M REVENUE $276.3M +16% Y/Y Gross profit: $205.6M · 74% margin GROSS PROFIT $205.6M 74% margin · +19% Y/Y Cost of revenue: $70.7M · 26% of revenue COST OF REVENUE $70.7M 26% of revenue Operating profit: $11.0M · 4% margin OPERATING PROFIT $11.0M 4% margin · +144% Y/Y Other income: $6.3M · 2% of revenue OTHER INCOME $6.3M 2% of revenue Operating expenses: $194.6M · 70% of revenue OPERATING EXPENSES $194.6M 70% of revenue Net profit: $16.5M · 6% margin NET PROFIT $16.5M 6% margin · +59% Y/Y Tax: $859K · 0% of revenue TAX $859K 0% of revenue R&D: $27.6M · 10% of revenue R&D $27.6M 10% of revenue SG&A: $167.0M · 60% of revenue SG&A $167.0M 60% of revenue

Where each $100 of sales went

FY2024
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 4.7% FY2020: 2.1% net income ÷ equity
Net margin 6.0% FY2020: 2.3% profit per $ of sales: 16.5M ÷ 276.3M
Asset turnover 0.57× FY2020: 0.60× sales per $ of assets: 276.3M ÷ 488.0M
Leverage 1.38× FY2020: 1.53× assets per $ of equity: 488.0M ÷ 354.6M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    10.3% vs 6.8%
  • Gross margin up over 5 years
    67.8% → 74.4%
  • Return on equity below 15%
    8.7%
  • A profit in 3 of 10 years
Net margin, FY2016 to FY2025: -36.0% to 6.0%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 17.5× interest expense
  • Current assets cover current liabilities
    Current ratio 5.13
Debt / equity at each year end, FY2016 to FY2025: 0.38 to 0.75

Cash and shareholders

  • Free cash flow positive in 5 of 10 years
    $24.7M last year
  • Share count up over 5 years
    +10.3%
  • Cash from operations above net income
    $51.9M vs $16.5M
Free cash flow, FY2016 to FY2025: -21.3M to 24.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

VCEL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue276.3M
FY2016: 54.4MFY2017: 63.9MFY2018: 90.9MFY2019: 117.8MFY2020: 124.2MFY2021: 156.2MFY2022: 164.4MFY2023: 197.5MFY2024: 237.2MFY2025: 276.3M FY2017FY2019FY2021FY2023FY2025
Net income16.5M
FY2016: -19.6MFY2017: -17.3MFY2018: -8.1MFY2019: -9.7MFY2020: 2.9MFY2021: -7.5MFY2022: -16.7MFY2023: -3.2MFY2024: 10.4MFY2025: 16.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow24.7M
FY2016: -21.3MFY2017: -14.7MFY2018: -3.1MFY2019: -9.8MFY2020: 14.9MFY2021: 21.1MFY2022: 10.1MFY2023: 15.3MFY2024: -5.8MFY2025: 24.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-14.0M
FY2016: -23.8MFY2017: -17.4MFY2018: -10.3MFY2019: -23.0MFY2020: 1.1MFY2021: -13.2MFY2022: -27.1MFY2023: -17.0MFY2024: -42.3MFY2025: -14.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.32
FY2016: -1.18FY2017: -0.52FY2018: -0.20FY2019: -0.22FY2020: 0.06FY2021: -0.16FY2022: -0.35FY2023: -0.07FY2024: 0.20FY2025: 0.32 FY2017FY2019FY2021FY2023FY2025
Diluted shares52.2M
FY2016: -FY2017: -FY2018: 40.2MFY2019: 44.2MFY2020: 47.3MFY2021: 46.5MFY2022: 47.1MFY2023: 47.6MFY2024: 51.7MFY2025: 52.2M FY2017FY2019FY2021FY2023FY2025

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue54.4M63.9M90.9M117.8M124.2M156.2M164.4M197.5M237.2M276.3M
Cost of revenue28.3M30.4M32.2M37.6M40.0M50.2M54.6M61.9M65.1M70.7M
Gross profit26.1M33.6M58.7M80.3M84.2M106.0M109.8M135.6M172.1M205.6M
R&D15.3M12.9M13.6M30.4M13.0M16.3M19.9M21.0M24.8M27.6M
SG&A27.4M35.6M49.0M61.1M68.8M97.6M106.9M121.0M142.8M167.0M
Operating income-19.2M-15.0M-3.9M-11.3M2.4M-7.9M-17.1M-6.5M4.5M11.0M
Interest expense15K92K31K8K6K4K366K600K614K630K
Pretax income-19.6M-17.3M-8.1M-9.7M3.0M-7.6M-16.0M-2.4M10.5M17.4M
Income tax0000180K-111K721K814K148K859K
Net income-19.6M-17.3M-8.1M-9.7M2.9M-7.5M-16.7M-3.2M10.4M16.5M
EPS (diluted)-1.18-0.52-0.20-0.220.06-0.16-0.35-0.070.200.32
Diluted shares--40.2M44.2M47.3M46.5M47.1M47.6M51.7M52.2M
Depreciation & amortization1.9M1.6M1.4M1.7M2.4M3.0M4.0M4.6M5.5M11.5M
EBITDA-17.4M-13.4M-2.5M-9.6M4.8M-4.9M-13.1M-1.8M10.0M22.6M
Gross margin47.9%52.5%64.6%68.1%67.8%67.9%66.8%68.6%72.6%74.4%
Operating margin-35.4%-23.4%-4.3%-9.5%1.9%-5.0%-10.4%-3.3%1.9%4.0%
Net margin-36.0%-27.0%-9.0%-8.2%2.3%-4.8%-10.2%-1.6%4.4%6.0%
Revenue growth+6.3%+17.5%+42.1%+29.7%+5.4%+25.8%+5.2%+20.2%+20.1%+16.5%
EPS growth-----to a loss---+60.0%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-19.9M-13.2M-412K-7.2M17.6M29.0M17.7M35.3M58.2M51.9M
Capital spending1.4M1.5M2.7M2.6M2.6M7.9M7.6M20.0M64.0M27.2M
Free cash flow-21.3M-14.7M-3.1M-9.8M14.9M21.1M10.1M15.3M-5.8M24.7M
Stock-based pay (added back)2.5M2.7M7.2M13.2M13.8M34.3M37.2M32.3M36.5M38.8M
Free cash flow after stock pay-23.8M-17.4M-10.3M-23.0M1.1M-13.2M-27.1M-17.0M-42.3M-14.0M
Acquisitions0---------
Debt repaid38K7.2M17.5M00-----
Investing cash flow-1.4M-1.5M-67.0M10.6M-17.2M-3.5M-36.2M-3.1M-79.0M-43.9M
Financing cash flow29.7M18.6M58.9M5.3M6.4M9.2M1.0M3.6M19.1M7.1M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.5M2.7M7.2M13.2M13.8M34.3M37.2M32.3M36.5M38.8M
Stock-based pay / revenue4.6%4.2%7.9%11.2%11.1%22.0%22.6%16.4%15.4%14.0%
Right-of-use assets--025.1M50.1M45.7M41.5M73.5M70.1M64.8M
Operating lease liabilities--027.7M53.2M50.1M47.6M88.0M98.8M96.3M
Finance lease liabilities---151K116K85K41K-686K638K

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.